{"gene":"OAS2","run_date":"2026-04-29T11:37:57","timeline":{"discoveries":[{"year":2025,"finding":"Human OAS2 exists in an auto-inhibited state as a zinc-mediated dimer. The catalytically deficient N-terminal OAS domain acts as a molecular ruler that prevents autoreactivity to short RNAs, providing a mechanism for dsRNA length discrimination. Dimerization and myristoylation localize OAS2 to Golgi membranes, and this membrane localization is required for OAS2 activation and restriction of viruses that exploit the endomembrane system (e.g., coronaviruses). A patient loss-of-function mutation in OAS2 was associated with autoimmune disease.","method":"Cryo-EM/crystal structure, in vitro enzymatic assays, mutagenesis, subcellular fractionation/live imaging, patient mutation analysis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — structure determination combined with mutagenesis, biochemical reconstitution, and localization with functional consequence in a single rigorous study","pmids":["40412389"],"is_preprint":false},{"year":2019,"finding":"OAS2 requires dsRNA of at least 35 bp for enzymatic activation (synthesis of 2'-5'-oligoadenylates), a substantially longer minimum length than OAS1 (19 bp). Both OAS2 domains are required for enzymatic activity, not just the domain containing the canonical catalytic aspartate triad. Activation efficiency is enhanced by 3'-overhangs on dsRNA without affecting binding affinity. Highly structured viral RNAs that activate OAS1 fail to activate OAS2 due to lack of extended dsRNA stretches >35 bp.","method":"In vitro enzymatic assay with recombinant purified OAS2 from eukaryotic cells, enzyme kinetics, domain mutagenesis","journal":"Biochemistry and cell biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with recombinant enzyme, kinetic characterization, and domain mutagenesis","pmids":["30965010"],"is_preprint":false},{"year":2025,"finding":"The OAS2 gene encodes two antiviral isoforms via alternative splicing: the shorter p69 isoform restricts seasonal coronavirus HCoV-OC43 replication via an RNase L-independent mechanism, while the longer p71 isoform restricts picornavirus EMCV replication via an RNase L-dependent mechanism. The distinct antiviral specificities are determined by the variable-length OAS2 C-terminal tail.","method":"Isoform-specific overexpression/knockdown, viral replication assays, RNase L-deficient cell lines, domain swap experiments","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — clean gain/loss-of-function with defined phenotypic readout and domain mapping; preprint not yet peer-reviewed","pmids":["bio_10.1101_2025.02.24.639105"],"is_preprint":true},{"year":2022,"finding":"An activating mutation in mouse Oas2 triggers a constitutive interferon response and prevents pregnancy-driven increases in mammary cancer metastases to lung in the MMTV-PyMT model. The Oas2 mutation also enhanced the efficacy of anti-PD-L1 checkpoint immunotherapy.","method":"N-ethyl-N-nitrosourea mutagenesis mouse model combined with MMTV-PyMT oncogene; Kaplan-Meier survival, immunohistochemistry, flow cytometry","journal":"Breast cancer research : BCR","confidence":"Medium","confidence_rationale":"Tier 2 — defined genetic mouse model with clear metastatic phenotype; single study","pmids":["35505346"],"is_preprint":false},{"year":2020,"finding":"OAS2 overexpression inhibits Zika virus replication by enhancing IFNβ expression and activating the JAK/STAT signaling pathway. OAS2 expression is induced by ZIKV infection through a RIG-I-dependent pathway.","method":"OAS2 overexpression by plasmid transfection and siRNA knockdown in A549 cells; RT-qPCR, Western blot, dual luciferase ISRE reporter assay, RNA-Seq","journal":"Viruses","confidence":"Medium","confidence_rationale":"Tier 2 — clean KD/OE with defined viral replication phenotype and pathway placement via epistasis (RIG-I dependence); single lab","pmids":["32276512"],"is_preprint":false},{"year":2022,"finding":"OAS2 overexpression in RKO colorectal cancer cells reduces invasion (>2-fold reduction) and promotes E-cadherin, β-catenin, and claudin-1 expression while suppressing N-cadherin and ZEB1, indicating OAS2 inhibits epithelial-mesenchymal transition. OAS2 overexpression also upregulates autophagy-related proteins (ATG5-12, ATG6/BECN1, ATG7, ATG101).","method":"OAS2 overexpression in RKO cells; invasion/migration assays, EMT marker Western blot/qPCR, autophagy protein analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function with defined cellular phenotype and molecular marker readout; single lab, single study","pmids":["30148861"],"is_preprint":false},{"year":2022,"finding":"Silencing of OAS2 (together with OAS1 and OAS3) inhibits phosphorylation of JAK1 and STAT1 in keratinocytes, and suppresses keratinocyte proliferation by inhibiting cell cycle progression.","method":"siRNA knockdown in normal human epidermal keratinocytes; Western blot for pJAK1/pSTAT1, cell cycle analysis","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 — KD with defined signaling and proliferation phenotype; OAS isoforms not individually separated, reducing isoform-specificity confidence","pmids":["35305973"],"is_preprint":false},{"year":2019,"finding":"OAS1, OAS2, and OAS3 restrict intracellular M. tuberculosis replication and enhance pro-inflammatory cytokine secretion (IL-1β, TNF-α, MCP-1). Silencing of OAS genes significantly increased M. tb CFU counts 96 h post-infection and decreased cytokine secretion.","method":"siRNA silencing in macrophages; CFU counting, Luminex cytokine assay","journal":"International journal of infectious diseases","confidence":"Low","confidence_rationale":"Tier 3 — KD phenotype without isoform-specific separation; OAS1/2/3 silenced together","pmids":["30822544"],"is_preprint":false},{"year":2022,"finding":"DUXAP10 pseudogene interacts with EZH2 histone methyltransferase to repress OAS2 expression, contributing to gefitinib resistance in NSCLC. Knockdown of DUXAP10 reversed gefitinib resistance both in vitro and in vivo.","method":"siRNA knockdown, Co-IP/pulldown of DUXAP10–EZH2 interaction, xenograft mouse model","journal":"Acta biochimica et biophysica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP for protein-RNA interaction plus in vivo validation; moderate evidence for EZH2-mediated OAS2 repression","pmids":["36471952"],"is_preprint":false},{"year":2023,"finding":"AT1R autoantibody (AT1-AA) activates AT1R and induces OAS2 upregulation in vascular smooth muscle cells (VSMCs); OAS2 siRNA knockdown reverses the AT1-AA-induced phenotypic transition (decreased contractile markers, increased synthetic markers) of VSMCs. In AT1R knockout rats, AT1-AA-induced phenotypic transition was absent, placing OAS2 downstream of AT1R in this pathway.","method":"Active immunization rat model, RNA-Seq, siRNA knockdown, Western blot for VSMC phenotype markers, AT1R knockout rats","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — KO epistasis plus KD phenotype rescue with defined molecular markers; single lab","pmids":["38092283"],"is_preprint":false},{"year":2019,"finding":"miR-340-5p directly targets OAS2 (and RIG-I) mRNA to repress antiviral immunity. Host cells reduce miR-340-5p levels during influenza A virus infection, allowing OAS2 upregulation as an antiviral defense mechanism.","method":"miRNA target prediction validated by luciferase reporter assay, miRNA inhibitor/mimic transfection, viral replication assay","journal":"Molecular therapy. Nucleic acids","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase reporter validates direct targeting plus functional viral replication phenotype; single study","pmids":["30753994"],"is_preprint":false},{"year":2009,"finding":"Activation of the 2-5OAS/RNase L pathway during CVB1 or HAV/18f infection in FRhK-4 cells does not require induced OAS1 or OAS2 expression; endogenous (constitutive) OAS levels suffice. Primarily OAS3 is detected during infection, and IFNβ treatment increasing all OAS isoforms does not enhance RNase L pathway activity or antiviral effect.","method":"Viral infection of FRhK-4 cells, RNase L activity assay, 2-5A detection, IFNβ pretreatment, Western blot for OAS isoforms","journal":"Virology","confidence":"Low","confidence_rationale":"Tier 3 — functional pathway assay but OAS2 role is inferred by absence rather than direct manipulation","pmids":["19383565"],"is_preprint":false}],"current_model":"OAS2 is an interferon-stimulated, double-stranded RNA-activated 2'-5'-oligoadenylate synthetase that exists as a zinc-mediated auto-inhibited dimer; its catalytically deficient domain acts as a molecular ruler requiring ≥35 bp dsRNA for activation, myristoylation and dimerization localize it to Golgi membranes where it activates RNase L to restrict endomembrane-exploiting viruses (e.g., coronaviruses), while alternative splicing generates two isoforms with distinct antiviral specificities and mechanisms (RNase L-dependent vs. independent), and loss-of-function is associated with autoimmune disease."},"narrative":{"teleology":[{"year":2009,"claim":"Early pathway-level studies showed that constitutive OAS protein levels suffice for 2-5A/RNase L pathway activation during certain viral infections, raising the question of whether OAS2 specifically contributes to antiviral defense or is functionally redundant with OAS1/OAS3.","evidence":"Viral infection of FRhK-4 cells with CVB1/HAV combined with RNase L activity assay and OAS Western blotting","pmids":["19383565"],"confidence":"Low","gaps":["OAS2 role inferred by absence rather than direct manipulation","No OAS2-specific knockdown or knockout performed","Single cell line system"]},{"year":2019,"claim":"Biochemical reconstitution established that OAS2 requires ≥35 bp dsRNA for activation — far longer than OAS1's 19 bp minimum — and that both OAS domains are necessary for catalytic activity, resolving the question of why OAS2 fails to respond to highly structured viral RNAs that activate OAS1.","evidence":"In vitro enzymatic assays with purified recombinant OAS2, enzyme kinetics, and domain mutagenesis","pmids":["30965010"],"confidence":"High","gaps":["Structural basis of dsRNA length discrimination was unknown at this point","In vivo relevance of the 35 bp threshold not tested","Role of 3'-overhangs in physiological activation unclear"]},{"year":2019,"claim":"Identification of miR-340-5p as a direct negative regulator of OAS2 mRNA revealed a host regulatory circuit whereby influenza A infection downregulates this miRNA to permit OAS2 upregulation as an antiviral response.","evidence":"Luciferase reporter assay confirming direct miR-340-5p targeting of OAS2 3'UTR, miRNA mimic/inhibitor transfection, viral replication assay","pmids":["30753994"],"confidence":"Medium","gaps":["Physiological miR-340-5p stoichiometry in relevant tissues not assessed","Contribution of OAS2 versus co-targeted RIG-I not separated"]},{"year":2020,"claim":"Functional gain- and loss-of-function experiments demonstrated that OAS2 restricts Zika virus replication through enhancement of IFNβ expression and JAK/STAT signaling, placing OAS2 not only downstream but also upstream of the interferon amplification loop via RIG-I-dependent induction.","evidence":"OAS2 overexpression/siRNA knockdown in A549 cells with RT-qPCR, ISRE reporter assay, and RNA-Seq","pmids":["32276512"],"confidence":"Medium","gaps":["Mechanism of OAS2-mediated IFNβ enhancement beyond RNase L not defined","Single cell line","Unclear if effect is direct or via 2-5A/RNase L cleavage products"]},{"year":2022,"claim":"An activating Oas2 mutation in mice demonstrated that constitutive OAS2 pathway activity can prevent pregnancy-driven mammary cancer metastasis and enhance anti-PD-L1 immunotherapy efficacy, establishing a role for OAS2 in tumor immune surveillance.","evidence":"ENU mutagenesis mouse model crossed with MMTV-PyMT; survival analysis, flow cytometry, immunohistochemistry","pmids":["35505346"],"confidence":"Medium","gaps":["Specific downstream effectors of the constitutive IFN response in this context not identified","Relevance to human cancer not established","Metastasis-specific versus general immune activation not resolved"]},{"year":2023,"claim":"OAS2 was placed downstream of AT1R signaling in vascular smooth muscle cells, where it mediates autoantibody-driven phenotypic switching from contractile to synthetic states, expanding OAS2 function beyond classical antiviral immunity.","evidence":"AT1R knockout rat model, RNA-Seq, OAS2 siRNA knockdown reversing VSMC phenotypic markers","pmids":["38092283"],"confidence":"Medium","gaps":["Whether OAS2 enzymatic activity (2-5A synthesis) is required for VSMC phenotype switching unknown","Mechanism connecting AT1R activation to OAS2 transcription not defined","Single lab observation"]},{"year":2025,"claim":"Cryo-EM and crystal structures revealed that OAS2 is auto-inhibited as a zinc-mediated dimer whose N-terminal catalytically deficient domain acts as a molecular ruler for dsRNA length discrimination; myristoylation-dependent Golgi localization was shown to be essential for activation and restriction of endomembrane-exploiting viruses, and a patient loss-of-function mutation was linked to autoimmune disease.","evidence":"Cryo-EM/crystal structure, in vitro enzymatic assays, mutagenesis, subcellular fractionation, live imaging, patient mutation analysis","pmids":["40412389"],"confidence":"High","gaps":["Full-length activated OAS2–dsRNA complex structure not yet captured","Mechanism linking OAS2 loss-of-function to autoimmunity versus viral susceptibility not dissected","Whether zinc-mediated dimerization is dynamically regulated in cells unknown"]},{"year":2025,"claim":"Alternative splicing was shown to generate two OAS2 isoforms (p69 and p71) with entirely distinct antiviral mechanisms and virus specificities, determined by the C-terminal tail — resolving why OAS2 can act through both RNase L-dependent and -independent pathways.","evidence":"Isoform-specific overexpression/knockdown, RNase L-deficient cell lines, domain swap experiments (preprint)","pmids":["bio_10.1101_2025.02.24.639105"],"confidence":"Medium","gaps":["Preprint; not yet peer-reviewed","RNase L-independent effector mechanism of p69 isoform uncharacterized","Relative expression levels and tissue-specific splicing of p69 versus p71 unknown"]},{"year":null,"claim":"Key open questions include the identity of the RNase L-independent effector pathway used by the p69 isoform, the structural basis of the activated OAS2–dsRNA complex, the mechanism connecting OAS2 loss-of-function to autoimmunity, and whether OAS2 enzymatic activity is required for its non-canonical roles in VSMC phenotype switching and EMT suppression.","evidence":"","pmids":[],"confidence":"Low","gaps":["No activated OAS2–dsRNA complex structure","RNase L-independent mechanism uncharacterized","Non-canonical (non-antiviral) functions lack mechanistic depth"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[0,1]},{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,2,4,10]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,8]}],"complexes":[],"partners":["RNASEL"],"other_free_text":[]},"mechanistic_narrative":"OAS2 is an interferon-stimulated 2'-5'-oligoadenylate synthetase that functions as a dsRNA sensor in innate antiviral immunity, coupling pathogen detection to RNase L activation and downstream restriction of viral replication. It exists as a zinc-mediated auto-inhibited dimer in which the catalytically deficient N-terminal OAS domain serves as a molecular ruler, requiring dsRNA of at least 35 bp for enzymatic activation — a stringency that distinguishes it from OAS1 and prevents autoreactivity to short endogenous RNAs [PMID:40412389, PMID:30965010]. Myristoylation and dimerization target OAS2 to Golgi membranes, and this endomembrane localization is essential for its activation and restriction of viruses such as coronaviruses that exploit the endomembrane system; a patient loss-of-function mutation in OAS2 is associated with autoimmune disease [PMID:40412389]. Alternative splicing generates two isoforms with distinct antiviral specificities: the shorter p69 isoform restricts coronaviruses via an RNase L-independent mechanism, while the longer p71 isoform restricts picornaviruses via RNase L, with specificity determined by the variable C-terminal tail [PMID:40412389, PMID:32276512]."},"prefetch_data":{"uniprot":{"accession":"P29728","full_name":"2'-5'-oligoadenylate synthase 2","aliases":["p69 OAS / p71 OAS","p69OAS / p71OAS"],"length_aa":719,"mass_kda":82.4,"function":"Interferon-induced, dsRNA-activated antiviral enzyme which plays a critical role in cellular innate antiviral response (PubMed:10464285, PubMed:9880569). Activated by detection of double stranded RNA (dsRNA): polymerizes higher oligomers of 2'-5'-oligoadenylates (2-5A) from ATP which then bind to the inactive monomeric form of ribonuclease L (RNASEL) leading to its dimerization and subsequent activation (PubMed:10464285, PubMed:11682059, PubMed:9880569). Activation of RNASEL leads to degradation of cellular as well as viral RNA, resulting in the inhibition of protein synthesis, thus terminating viral replication (PubMed:10464285, PubMed:9880569). Can mediate the antiviral effect via the classical RNASEL-dependent pathway or an alternative antiviral pathway independent of RNASEL (PubMed:21142819). In addition, it may also play a role in other cellular processes such as apoptosis, cell growth, differentiation and gene regulation (PubMed:21142819). May act as a negative regulator of lactation, stopping lactation in virally infected mammary gland lobules, thereby preventing transmission of viruses to neonates (By similarity). Non-infected lobules would not be affected, allowing efficient pup feeding during infection (By similarity)","subcellular_location":"Cytoplasm; Cytoplasm, perinuclear region","url":"https://www.uniprot.org/uniprotkb/P29728/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/OAS2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/OAS2","total_profiled":1310},"omim":[{"mim_id":"621409","title":"AUTOINFLAMMATION AND AUTOIMMUNITY, SYSTEMIC, WITH IMMUNE DYSREGULATION 2; AIAISD2","url":"https://www.omim.org/entry/621409"},{"mim_id":"616414","title":"AUTOINFLAMMATION AND AUTOIMMUNITY, SYSTEMIC, WITH IMMUNE DYSREGULATION 1; AIAISD1","url":"https://www.omim.org/entry/616414"},{"mim_id":"609418","title":"MICRO RNA 19A; MIR19A","url":"https://www.omim.org/entry/609418"},{"mim_id":"603351","title":"2-PRIME,5-PRIME-@OLIGOADENYLATE SYNTHETASE 3; OAS3","url":"https://www.omim.org/entry/603351"},{"mim_id":"603350","title":"2-PRIME,5-PRIME-@OLIGOADENYLATE SYNTHETASE 2; OAS2","url":"https://www.omim.org/entry/603350"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Centrosome","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"salivary gland","ntpm":63.3}],"url":"https://www.proteinatlas.org/search/OAS2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P29728","domains":[{"cath_id":"3.30.460.10","chopping":"28-148","consensus_level":"medium","plddt":90.6563,"start":28,"end":148},{"cath_id":"1.10.1410.20","chopping":"363-670","consensus_level":"medium","plddt":91.2331,"start":363,"end":670}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P29728","model_url":"https://alphafold.ebi.ac.uk/files/AF-P29728-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P29728-F1-predicted_aligned_error_v6.png","plddt_mean":88.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=OAS2","jax_strain_url":"https://www.jax.org/strain/search?query=OAS2"},"sequence":{"accession":"P29728","fasta_url":"https://rest.uniprot.org/uniprotkb/P29728.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P29728/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P29728"}},"corpus_meta":[{"pmid":"30822544","id":"PMC_30822544","title":"OAS1, OAS2 and OAS3 restrict intracellular M. tb replication and enhance cytokine secretion.","date":"2019","source":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","url":"https://pubmed.ncbi.nlm.nih.gov/30822544","citation_count":44,"is_preprint":false},{"pmid":"32321151","id":"PMC_32321151","title":"MALAT1 is involved in type I IFNs-mediated systemic lupus erythematosus by up-regulating OAS2, OAS3, and OASL.","date":"2020","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/32321151","citation_count":41,"is_preprint":false},{"pmid":"32276512","id":"PMC_32276512","title":"2', 5'-Oligoadenylate Synthetase 2 (OAS2) Inhibits Zika Virus Replication through Activation of Type Ι IFN Signaling Pathway.","date":"2020","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/32276512","citation_count":34,"is_preprint":false},{"pmid":"30148861","id":"PMC_30148861","title":"Opposite functions of GSN and OAS2 on colorectal cancer metastasis, mediating perineural and lymphovascular invasion, respectively.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30148861","citation_count":34,"is_preprint":false},{"pmid":"35305973","id":"PMC_35305973","title":"OAS1, OAS2, and OAS3 Contribute to Epidermal Keratinocyte Proliferation by Regulating Cell Cycle and Augmenting IFN-1‒Induced Jak1‒Signal Transducer and Activator of Transcription 1 Phosphorylation in Psoriasis.","date":"2022","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/35305973","citation_count":33,"is_preprint":false},{"pmid":"30753994","id":"PMC_30753994","title":"The Downregulation of MicroRNA hsa-miR-340-5p in IAV-Infected A549 Cells Suppresses Viral Replication by Targeting RIG-I and OAS2.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/30753994","citation_count":32,"is_preprint":false},{"pmid":"32849499","id":"PMC_32849499","title":"Quantitative Proteomic Profile of Psoriatic Epidermis Identifies OAS2 as a Novel Biomarker for Disease Activity.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32849499","citation_count":26,"is_preprint":false},{"pmid":"27572959","id":"PMC_27572959","title":"Epigenetic regulation of OAS2 shows disease-specific DNA methylation profiles at individual CpG sites.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27572959","citation_count":23,"is_preprint":false},{"pmid":"30965010","id":"PMC_30965010","title":"Impact of double-stranded RNA characteristics on the activation of human 2'-5'-oligoadenylate synthetase 2 (OAS2).","date":"2019","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/30965010","citation_count":21,"is_preprint":false},{"pmid":"28139728","id":"PMC_28139728","title":"Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28139728","citation_count":21,"is_preprint":false},{"pmid":"19383565","id":"PMC_19383565","title":"Activation of the 2-5OAS/RNase L pathway in CVB1 or HAV/18f infected FRhK-4 cells does not require induction of OAS1 or OAS2 expression.","date":"2009","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/19383565","citation_count":17,"is_preprint":false},{"pmid":"36710986","id":"PMC_36710986","title":"piR-36249 and DHX36 together inhibit testicular cancer cells progression by upregulating OAS2.","date":"2023","source":"Non-coding RNA research","url":"https://pubmed.ncbi.nlm.nih.gov/36710986","citation_count":14,"is_preprint":false},{"pmid":"24328427","id":"PMC_24328427","title":"Differential upregulation of human 2'5'OAS genes on systemic sclerosis: Detection of increased basal levels of OASL and OAS2 genes through a qPCR based assay.","date":"2013","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/24328427","citation_count":12,"is_preprint":false},{"pmid":"36471952","id":"PMC_36471952","title":"The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression.","date":"2022","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/36471952","citation_count":10,"is_preprint":false},{"pmid":"35505346","id":"PMC_35505346","title":"Activation of the viral sensor oligoadenylate synthetase 2 (Oas2) prevents pregnancy-driven mammary cancer metastases.","date":"2022","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/35505346","citation_count":10,"is_preprint":false},{"pmid":"24594345","id":"PMC_24594345","title":"Association between polymorphisms in OAS2 and CD209 genes and predisposition to chronic hepatitis C in Russian population.","date":"2014","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/24594345","citation_count":8,"is_preprint":false},{"pmid":"40412389","id":"PMC_40412389","title":"Structural basis for OAS2 regulation and its antiviral function.","date":"2025","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/40412389","citation_count":4,"is_preprint":false},{"pmid":"37662498","id":"PMC_37662498","title":"Letter to editor regarding \"piR-36249 and DHX36 together inhibit testicular cancer cells progression by upregulating OAS2\".","date":"2023","source":"Non-coding RNA research","url":"https://pubmed.ncbi.nlm.nih.gov/37662498","citation_count":2,"is_preprint":false},{"pmid":"38092283","id":"PMC_38092283","title":"AT1R autoantibody promotes phenotypic transition of smooth muscle cells by activating AT1R-OAS2.","date":"2023","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38092283","citation_count":1,"is_preprint":false},{"pmid":"41186887","id":"PMC_41186887","title":"A functional NKILA variant (rs2273534) drives genetic susceptibility and oncogenic progression in gastric cancer via the miR-4424/OAS2 pathway.","date":"2025","source":"Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association","url":"https://pubmed.ncbi.nlm.nih.gov/41186887","citation_count":1,"is_preprint":false},{"pmid":"39416786","id":"PMC_39416786","title":"Genetic variants of LRRC8C, OAS2, and CCL25 in the T cell exhaustion-related genes are associated with non-small cell lung cancer survival.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39416786","citation_count":1,"is_preprint":false},{"pmid":"40545977","id":"PMC_40545977","title":"Hypomethylation of OAS2 and OAS3 Gene Promoters: Insights into the ‎Pathogenesis of Systemic Lupus Erythematosus.","date":"2025","source":"Iranian journal of immunology : IJI","url":"https://pubmed.ncbi.nlm.nih.gov/40545977","citation_count":0,"is_preprint":false},{"pmid":"40124961","id":"PMC_40124961","title":"Corrigendum to \"piR-36249 and DHX36 together inhibit testicular cancer cells progression by upregulating OAS2\" [Noncoding RNA Research 2023 8 (2) 174-186].","date":"2025","source":"Non-coding RNA research","url":"https://pubmed.ncbi.nlm.nih.gov/40124961","citation_count":0,"is_preprint":false},{"pmid":"40480194","id":"PMC_40480194","title":"Finding a foothold to fight: New insights into the viral RNA sensing and activation mechanism of OAS2.","date":"2025","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/40480194","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.02.24.639105","title":"Alternative splicing broadens antiviral diversity at the human <i>OAS2</i> locus","date":"2025-02-24","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.24.639105","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.07.606975","title":"Research on the Mechanism of Lphn1 Knockout in Inhibiting Colorectal Cancer","date":"2024-08-09","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.07.606975","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.18.619140","title":"The Role of ISG15 in Cancer Biology: Systematic Evaluation of ISG15 Expression and Its Molecular Interactions in a Pan-Cancer Context","date":"2024-10-21","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.18.619140","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14217,"output_tokens":3043,"usd":0.044148},"stage2":{"model":"claude-opus-4-6","input_tokens":6412,"output_tokens":2409,"usd":0.138428},"total_usd":0.182576,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2025,\n      \"finding\": \"Human OAS2 exists in an auto-inhibited state as a zinc-mediated dimer. The catalytically deficient N-terminal OAS domain acts as a molecular ruler that prevents autoreactivity to short RNAs, providing a mechanism for dsRNA length discrimination. Dimerization and myristoylation localize OAS2 to Golgi membranes, and this membrane localization is required for OAS2 activation and restriction of viruses that exploit the endomembrane system (e.g., coronaviruses). A patient loss-of-function mutation in OAS2 was associated with autoimmune disease.\",\n      \"method\": \"Cryo-EM/crystal structure, in vitro enzymatic assays, mutagenesis, subcellular fractionation/live imaging, patient mutation analysis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure determination combined with mutagenesis, biochemical reconstitution, and localization with functional consequence in a single rigorous study\",\n      \"pmids\": [\"40412389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"OAS2 requires dsRNA of at least 35 bp for enzymatic activation (synthesis of 2'-5'-oligoadenylates), a substantially longer minimum length than OAS1 (19 bp). Both OAS2 domains are required for enzymatic activity, not just the domain containing the canonical catalytic aspartate triad. Activation efficiency is enhanced by 3'-overhangs on dsRNA without affecting binding affinity. Highly structured viral RNAs that activate OAS1 fail to activate OAS2 due to lack of extended dsRNA stretches >35 bp.\",\n      \"method\": \"In vitro enzymatic assay with recombinant purified OAS2 from eukaryotic cells, enzyme kinetics, domain mutagenesis\",\n      \"journal\": \"Biochemistry and cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with recombinant enzyme, kinetic characterization, and domain mutagenesis\",\n      \"pmids\": [\"30965010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The OAS2 gene encodes two antiviral isoforms via alternative splicing: the shorter p69 isoform restricts seasonal coronavirus HCoV-OC43 replication via an RNase L-independent mechanism, while the longer p71 isoform restricts picornavirus EMCV replication via an RNase L-dependent mechanism. The distinct antiviral specificities are determined by the variable-length OAS2 C-terminal tail.\",\n      \"method\": \"Isoform-specific overexpression/knockdown, viral replication assays, RNase L-deficient cell lines, domain swap experiments\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean gain/loss-of-function with defined phenotypic readout and domain mapping; preprint not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.02.24.639105\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"An activating mutation in mouse Oas2 triggers a constitutive interferon response and prevents pregnancy-driven increases in mammary cancer metastases to lung in the MMTV-PyMT model. The Oas2 mutation also enhanced the efficacy of anti-PD-L1 checkpoint immunotherapy.\",\n      \"method\": \"N-ethyl-N-nitrosourea mutagenesis mouse model combined with MMTV-PyMT oncogene; Kaplan-Meier survival, immunohistochemistry, flow cytometry\",\n      \"journal\": \"Breast cancer research : BCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined genetic mouse model with clear metastatic phenotype; single study\",\n      \"pmids\": [\"35505346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"OAS2 overexpression inhibits Zika virus replication by enhancing IFNβ expression and activating the JAK/STAT signaling pathway. OAS2 expression is induced by ZIKV infection through a RIG-I-dependent pathway.\",\n      \"method\": \"OAS2 overexpression by plasmid transfection and siRNA knockdown in A549 cells; RT-qPCR, Western blot, dual luciferase ISRE reporter assay, RNA-Seq\",\n      \"journal\": \"Viruses\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KD/OE with defined viral replication phenotype and pathway placement via epistasis (RIG-I dependence); single lab\",\n      \"pmids\": [\"32276512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"OAS2 overexpression in RKO colorectal cancer cells reduces invasion (>2-fold reduction) and promotes E-cadherin, β-catenin, and claudin-1 expression while suppressing N-cadherin and ZEB1, indicating OAS2 inhibits epithelial-mesenchymal transition. OAS2 overexpression also upregulates autophagy-related proteins (ATG5-12, ATG6/BECN1, ATG7, ATG101).\",\n      \"method\": \"OAS2 overexpression in RKO cells; invasion/migration assays, EMT marker Western blot/qPCR, autophagy protein analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with defined cellular phenotype and molecular marker readout; single lab, single study\",\n      \"pmids\": [\"30148861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Silencing of OAS2 (together with OAS1 and OAS3) inhibits phosphorylation of JAK1 and STAT1 in keratinocytes, and suppresses keratinocyte proliferation by inhibiting cell cycle progression.\",\n      \"method\": \"siRNA knockdown in normal human epidermal keratinocytes; Western blot for pJAK1/pSTAT1, cell cycle analysis\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD with defined signaling and proliferation phenotype; OAS isoforms not individually separated, reducing isoform-specificity confidence\",\n      \"pmids\": [\"35305973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"OAS1, OAS2, and OAS3 restrict intracellular M. tuberculosis replication and enhance pro-inflammatory cytokine secretion (IL-1β, TNF-α, MCP-1). Silencing of OAS genes significantly increased M. tb CFU counts 96 h post-infection and decreased cytokine secretion.\",\n      \"method\": \"siRNA silencing in macrophages; CFU counting, Luminex cytokine assay\",\n      \"journal\": \"International journal of infectious diseases\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — KD phenotype without isoform-specific separation; OAS1/2/3 silenced together\",\n      \"pmids\": [\"30822544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DUXAP10 pseudogene interacts with EZH2 histone methyltransferase to repress OAS2 expression, contributing to gefitinib resistance in NSCLC. Knockdown of DUXAP10 reversed gefitinib resistance both in vitro and in vivo.\",\n      \"method\": \"siRNA knockdown, Co-IP/pulldown of DUXAP10–EZH2 interaction, xenograft mouse model\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP for protein-RNA interaction plus in vivo validation; moderate evidence for EZH2-mediated OAS2 repression\",\n      \"pmids\": [\"36471952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"AT1R autoantibody (AT1-AA) activates AT1R and induces OAS2 upregulation in vascular smooth muscle cells (VSMCs); OAS2 siRNA knockdown reverses the AT1-AA-induced phenotypic transition (decreased contractile markers, increased synthetic markers) of VSMCs. In AT1R knockout rats, AT1-AA-induced phenotypic transition was absent, placing OAS2 downstream of AT1R in this pathway.\",\n      \"method\": \"Active immunization rat model, RNA-Seq, siRNA knockdown, Western blot for VSMC phenotype markers, AT1R knockout rats\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO epistasis plus KD phenotype rescue with defined molecular markers; single lab\",\n      \"pmids\": [\"38092283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-340-5p directly targets OAS2 (and RIG-I) mRNA to repress antiviral immunity. Host cells reduce miR-340-5p levels during influenza A virus infection, allowing OAS2 upregulation as an antiviral defense mechanism.\",\n      \"method\": \"miRNA target prediction validated by luciferase reporter assay, miRNA inhibitor/mimic transfection, viral replication assay\",\n      \"journal\": \"Molecular therapy. Nucleic acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase reporter validates direct targeting plus functional viral replication phenotype; single study\",\n      \"pmids\": [\"30753994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Activation of the 2-5OAS/RNase L pathway during CVB1 or HAV/18f infection in FRhK-4 cells does not require induced OAS1 or OAS2 expression; endogenous (constitutive) OAS levels suffice. Primarily OAS3 is detected during infection, and IFNβ treatment increasing all OAS isoforms does not enhance RNase L pathway activity or antiviral effect.\",\n      \"method\": \"Viral infection of FRhK-4 cells, RNase L activity assay, 2-5A detection, IFNβ pretreatment, Western blot for OAS isoforms\",\n      \"journal\": \"Virology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — functional pathway assay but OAS2 role is inferred by absence rather than direct manipulation\",\n      \"pmids\": [\"19383565\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"OAS2 is an interferon-stimulated, double-stranded RNA-activated 2'-5'-oligoadenylate synthetase that exists as a zinc-mediated auto-inhibited dimer; its catalytically deficient domain acts as a molecular ruler requiring ≥35 bp dsRNA for activation, myristoylation and dimerization localize it to Golgi membranes where it activates RNase L to restrict endomembrane-exploiting viruses (e.g., coronaviruses), while alternative splicing generates two isoforms with distinct antiviral specificities and mechanisms (RNase L-dependent vs. independent), and loss-of-function is associated with autoimmune disease.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"OAS2 is an interferon-stimulated 2'-5'-oligoadenylate synthetase that functions as a dsRNA sensor in innate antiviral immunity, coupling pathogen detection to RNase L activation and downstream restriction of viral replication. It exists as a zinc-mediated auto-inhibited dimer in which the catalytically deficient N-terminal OAS domain serves as a molecular ruler, requiring dsRNA of at least 35 bp for enzymatic activation — a stringency that distinguishes it from OAS1 and prevents autoreactivity to short endogenous RNAs [PMID:40412389, PMID:30965010]. Myristoylation and dimerization target OAS2 to Golgi membranes, and this endomembrane localization is essential for its activation and restriction of viruses such as coronaviruses that exploit the endomembrane system; a patient loss-of-function mutation in OAS2 is associated with autoimmune disease [PMID:40412389]. Alternative splicing generates two isoforms with distinct antiviral specificities: the shorter p69 isoform restricts coronaviruses via an RNase L-independent mechanism, while the longer p71 isoform restricts picornaviruses via RNase L, with specificity determined by the variable C-terminal tail [PMID:40412389, PMID:32276512].\",\n  \"teleology\": [\n    {\n      \"year\": 2009,\n      \"claim\": \"Early pathway-level studies showed that constitutive OAS protein levels suffice for 2-5A/RNase L pathway activation during certain viral infections, raising the question of whether OAS2 specifically contributes to antiviral defense or is functionally redundant with OAS1/OAS3.\",\n      \"evidence\": \"Viral infection of FRhK-4 cells with CVB1/HAV combined with RNase L activity assay and OAS Western blotting\",\n      \"pmids\": [\"19383565\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"OAS2 role inferred by absence rather than direct manipulation\", \"No OAS2-specific knockdown or knockout performed\", \"Single cell line system\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Biochemical reconstitution established that OAS2 requires ≥35 bp dsRNA for activation — far longer than OAS1's 19 bp minimum — and that both OAS domains are necessary for catalytic activity, resolving the question of why OAS2 fails to respond to highly structured viral RNAs that activate OAS1.\",\n      \"evidence\": \"In vitro enzymatic assays with purified recombinant OAS2, enzyme kinetics, and domain mutagenesis\",\n      \"pmids\": [\"30965010\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of dsRNA length discrimination was unknown at this point\", \"In vivo relevance of the 35 bp threshold not tested\", \"Role of 3'-overhangs in physiological activation unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of miR-340-5p as a direct negative regulator of OAS2 mRNA revealed a host regulatory circuit whereby influenza A infection downregulates this miRNA to permit OAS2 upregulation as an antiviral response.\",\n      \"evidence\": \"Luciferase reporter assay confirming direct miR-340-5p targeting of OAS2 3'UTR, miRNA mimic/inhibitor transfection, viral replication assay\",\n      \"pmids\": [\"30753994\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological miR-340-5p stoichiometry in relevant tissues not assessed\", \"Contribution of OAS2 versus co-targeted RIG-I not separated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Functional gain- and loss-of-function experiments demonstrated that OAS2 restricts Zika virus replication through enhancement of IFNβ expression and JAK/STAT signaling, placing OAS2 not only downstream but also upstream of the interferon amplification loop via RIG-I-dependent induction.\",\n      \"evidence\": \"OAS2 overexpression/siRNA knockdown in A549 cells with RT-qPCR, ISRE reporter assay, and RNA-Seq\",\n      \"pmids\": [\"32276512\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of OAS2-mediated IFNβ enhancement beyond RNase L not defined\", \"Single cell line\", \"Unclear if effect is direct or via 2-5A/RNase L cleavage products\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"An activating Oas2 mutation in mice demonstrated that constitutive OAS2 pathway activity can prevent pregnancy-driven mammary cancer metastasis and enhance anti-PD-L1 immunotherapy efficacy, establishing a role for OAS2 in tumor immune surveillance.\",\n      \"evidence\": \"ENU mutagenesis mouse model crossed with MMTV-PyMT; survival analysis, flow cytometry, immunohistochemistry\",\n      \"pmids\": [\"35505346\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific downstream effectors of the constitutive IFN response in this context not identified\", \"Relevance to human cancer not established\", \"Metastasis-specific versus general immune activation not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"OAS2 was placed downstream of AT1R signaling in vascular smooth muscle cells, where it mediates autoantibody-driven phenotypic switching from contractile to synthetic states, expanding OAS2 function beyond classical antiviral immunity.\",\n      \"evidence\": \"AT1R knockout rat model, RNA-Seq, OAS2 siRNA knockdown reversing VSMC phenotypic markers\",\n      \"pmids\": [\"38092283\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether OAS2 enzymatic activity (2-5A synthesis) is required for VSMC phenotype switching unknown\", \"Mechanism connecting AT1R activation to OAS2 transcription not defined\", \"Single lab observation\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Cryo-EM and crystal structures revealed that OAS2 is auto-inhibited as a zinc-mediated dimer whose N-terminal catalytically deficient domain acts as a molecular ruler for dsRNA length discrimination; myristoylation-dependent Golgi localization was shown to be essential for activation and restriction of endomembrane-exploiting viruses, and a patient loss-of-function mutation was linked to autoimmune disease.\",\n      \"evidence\": \"Cryo-EM/crystal structure, in vitro enzymatic assays, mutagenesis, subcellular fractionation, live imaging, patient mutation analysis\",\n      \"pmids\": [\"40412389\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length activated OAS2–dsRNA complex structure not yet captured\", \"Mechanism linking OAS2 loss-of-function to autoimmunity versus viral susceptibility not dissected\", \"Whether zinc-mediated dimerization is dynamically regulated in cells unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Alternative splicing was shown to generate two OAS2 isoforms (p69 and p71) with entirely distinct antiviral mechanisms and virus specificities, determined by the C-terminal tail — resolving why OAS2 can act through both RNase L-dependent and -independent pathways.\",\n      \"evidence\": \"Isoform-specific overexpression/knockdown, RNase L-deficient cell lines, domain swap experiments (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.02.24.639105\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint; not yet peer-reviewed\", \"RNase L-independent effector mechanism of p69 isoform uncharacterized\", \"Relative expression levels and tissue-specific splicing of p69 versus p71 unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the identity of the RNase L-independent effector pathway used by the p69 isoform, the structural basis of the activated OAS2–dsRNA complex, the mechanism connecting OAS2 loss-of-function to autoimmunity, and whether OAS2 enzymatic activity is required for its non-canonical roles in VSMC phenotype switching and EMT suppression.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No activated OAS2–dsRNA complex structure\", \"RNase L-independent mechanism uncharacterized\", \"Non-canonical (non-antiviral) functions lack mechanistic depth\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 2, 4, 10]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"RNASEL\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}